Patents by Inventor Akira Tanokura

Akira Tanokura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11739143
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: August 29, 2023
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME LLC
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Publication number: 20230192868
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Application
    Filed: March 2, 2023
    Publication date: June 22, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Hiroshi EGUCHI, Akira Tanokura, Kenichiro Takagi, Hirotsugu KATO, Satoshi YAMAMURA, Naoko NAMIKI
  • Patent number: 11629194
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: April 18, 2023
    Assignee: Teijin Pharma Limited
    Inventors: Hiroshi Eguchi, Akira Tanokura, Kenichiro Takagi, Hirotsugu Kato, Satoshi Yamamura, Naoko Namiki
  • Publication number: 20220033485
    Abstract: Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: Teijin Pharma Limited
    Inventors: Akira TANOKURA, Hirotsugu KATO, Hiroshi EGUCHI, Kenichiro TAKAGI, Satoshi YAMAMURA, Naoko NAMIKI, Daisuke ISHIKAWA, Hirofumi HIGUCHI, Tomoyo TAKEO, Masayo OHORI
  • Publication number: 20210380677
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Application
    Filed: December 15, 2020
    Publication date: December 9, 2021
    Applicants: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Patent number: 10894829
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: January 19, 2021
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Publication number: 20200223916
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 16, 2020
    Applicants: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Publication number: 20200115460
    Abstract: The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
    Type: Application
    Filed: May 29, 2018
    Publication date: April 16, 2020
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Hiroshi EGUCHI, Akira TANOKURA, Kenichiro TAKAGI, Hirotsugu KATO, Satoshi YAMAMURA, Naoko NAMIKI
  • Patent number: 10556950
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 11, 2020
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Publication number: 20180346564
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 6, 2018
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Patent number: 9617240
    Abstract: Provided are a compound expressed by formula (I) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [In the formula, A, X, Y, Z, R, and R1 have the meaning set forth in claim 1].
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: April 11, 2017
    Assignee: Teijin Pharma Limited
    Inventors: Asahi Kawana, Chikashi Kanazawa, Masayuki Tera, Yoshimasa Takahashi, Mariko Imazeki, Hiroyuki Takahashi, Akira Tanokura
  • Publication number: 20160039784
    Abstract: Provided are a compound expressed by formula (I) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [In the formula, A, X, Y, Z, R, and R1 have the meaning set forth in claim 1].
    Type: Application
    Filed: March 28, 2014
    Publication date: February 11, 2016
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Asahi KAWANA, Chikashi KANAZAWA, Masayuki TERA, Yoshimasa TAKAHASHI, Mariko IMAZEKI, Hiroyuki TAKAHASHI, Akira TANOKURA
  • Patent number: 7071359
    Abstract: A compound represented by the Formula below, and an agent for the remedy of neural damage having the said compound as the active ingredient. [Here, G represents G1 shown below R4 represents, hydrogen atoms and acyl groups, W represents single bonds and alkylenes, m represents 0 or 1, R5 and R6 represent hydrogen atoms, aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, aromatic hydrocarbon groups and heterocyclic groups, and R7 represents hydrogen atoms, acyl groups and alkoxycarbonyl groups. A2 represents, single bonds, —O—, —NR3—, and —S(?O)n—, A1 and A3 represent single bonds, aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, heterocyclic groups and phenylene groups, and A4 represents single bonds, carbonyl groups and aliphatic hydrocarbon groups. R1 and R2 represent hydrogen atoms, alkyl groups, cycloalkyl groups, phenyl groups and heterocyclic groups. The previously mentioned functional groups may be substituted.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: July 4, 2006
    Assignee: Teijin Limited
    Inventors: Satoshi Sugiura, Takaharu Tsutsumi, Yorimasa Suwa, Takami Arai, Katsutoshi Sakurai, Noboru Yoshioka, Akira Tanokura, Jun Suzuki